Cargando…
“Liquid elbows” due to afatinib administration
Non-small cell lung cancer adenocarcinoma in the past decade has targeted therapies as the cornerstone for therapy. In specific patients with epidermal growth factor receptor mutation have three different therapy approaches with the tyrosine kinase inhibitors: erlotinib, gefitinib and afatinib. Nowa...
Autores principales: | Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Porpodis, Konstantinos, Kallianos, Anastasios, Rapti, Aggeliki, Trakada, Georgia, Velentza, Lemonia, Huang, Haidong, Tsiouda, Theodora, Hohenforst-Schmidt, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491760/ https://www.ncbi.nlm.nih.gov/pubmed/28702338 http://dx.doi.org/10.1016/j.rmcr.2017.06.013 |
Ejemplares similares
-
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma
por: Zarogoulidis, Paul, et al.
Publicado: (2017) -
Clinical differences between H3N2 and H1N1 influenza 2012 and lower respiratory tract infection found using a statistical classification approach
por: Petridis, Dimitris, et al.
Publicado: (2014)